Advertisement

Appendageal Malignancies

  • Catherine A. Harwood
  • Charlotte M. Proby
  • Rino Cerio
Part of the Cancer Treatment and Research book series (CTAR, volume 146)

Appendageal tumours (ATs) are neoplasms in which differentiation occurs toward one or more adnexal structures of the skin. The increased incidence, clinicopathologic spectrum and prognosis of keratinocyte skin cancers in organ transplant recipients (OTR) have all been well documented in recent years. In contrast, there are few publications relating to post-transplant ATs. Available reports provide evidence for a probable increased incidence of at least some of these neoplasms in OTRs. However, most published studies are essentially anecdotal observations or small case series, few data are available from systematic transplant cohort studies, and there is a dearth of reliable information on the prevalence of ATs in the general population. Such factors place major limitations on attempts to accurately assess relative risk of these tumours in OTRs.

Keywords

Sebaceous Gland Merkel Cell Carcinoma Organ Transplant Recipient Sebaceous Carcinoma Sebaceous Adenoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    LeBoit PE. Appendageal skin tumours: Introduction. In: World Health Organisation Classification of Tumours: Skin Tumours (Edited by LeBoit PE, Burg G, Weedon D, Sarasin A); IARC Press, Lyon, 2006. pp 123–4.Google Scholar
  2. 2.
    Alsaad KO, Obaidat NA, Ghazarian D. Skin adnexal neoplasms–part 1: an approach to tumours of the pilosebaceous unit. J Clin Pathol. 2007; 60:129–44.PubMedCrossRefGoogle Scholar
  3. 3.
    Levi Z, Hazazi R, Kedar-Barnes I, Hodak E, Gal E, Mor E, Niv Y, Winkler J.. Switching from tacrolimus to sirolimus halts the appearance of new sebaceous neoplasms in Muir-Torre syndrome. Am J Transplant. 2007; 7(2):476–9.PubMedCrossRefGoogle Scholar
  4. 4.
    Kazakov DV, Calonje E, Zelger B, Luzar B, Belousova IE, Mukensnabl P, Michal M. Sebaceous carcinoma arising in nevus sebaceus of Jadassohn: a clinicopathological study of five cases. Am J Dermatopathol. 2007; 29(3):242–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Liegl B, Leibl S, Okcu M, Beham-Schmid C, Regauer S. Malignant transformation within benign adnexal skin tumours. Histopathology. 2004; 45(2):162–70.PubMedCrossRefGoogle Scholar
  6. 6.
    Kose R, Coban YK, Ciralik H. Eccrine porocarcinoma arising from preexisting eccrine poroma of the scalp after radiotherapy for cervical cancer. Dermatol Online J. 2006; 12(6):18.PubMedGoogle Scholar
  7. 7.
    Obaidat NA, Alsaad KO, Ghazarian D. Skin adnexal neoplasms–part 2: an approach to tumours of cutaneous sweat glands. J Clin Pathol. 2007; 60:145–59.PubMedCrossRefGoogle Scholar
  8. 8.
    Stone MS, Duncan WC, McGavran MH. Torre’s syndrome: exacerbation of cutaneous manifestations with immunosuppression. J Am Acad Dermatol. 1986; 15:1101–3.PubMedCrossRefGoogle Scholar
  9. 9.
    Warschaw KE, Eble JN, Hood AF, Wolverton SE, Halling KC. The Muir-Torre syndrome in a black patient with AIDS: histopathology and molecular genetic studies. J Cutan Pathol. 1997:24;511–518.PubMedCrossRefGoogle Scholar
  10. 10.
    Dover JS, Ashur ML, Kwan TH. Sebaceous adenoma in a patient with acquired immunodeficiency syndrome. Arch Dermatol. 1988; 124:489–90.PubMedCrossRefGoogle Scholar
  11. 11.
    Paraf F, Sasseville D, Watters AK, Naod S, Ginsburg O, Shibata H, Jothy S. Clinicopathological relevance of the association between gastrointestinal and sebaceous neoplasms: the Muir-Torre syndrome. Hum Pathol. 1995; 26:422–7.PubMedCrossRefGoogle Scholar
  12. 12.
    Stockl FA, Dolmetsch AM, Codère F, Burnier MN. Sebaceous carcinoma of the eyelid in an immunocompromised patient with Muir-Torre syndrome. Can J Opthalmol. 1995; 30:324–6.Google Scholar
  13. 13.
    Yen MT, Tse DT. Sebaceous cell carcinoma of the eyelid and the human immunodeficiency virus. Opthal Plast Reconstr Surg. 2000; 16:206–10.CrossRefGoogle Scholar
  14. 14.
    Kuwahara RT, Rudolph TM, Skinner RB, Rasberry RD. A large ulcerated tumour on the back. Arch Dermatol. 2001; 137:1367–72.PubMedGoogle Scholar
  15. 15.
    Mahlberg MJ, McGinnis KS, Draft KS, Fakharzadeh SS. Multiple eccrine poromas in the setting of total body irradiation and immunosuppression. J Am Acad Dermatol. 2006 Aug;55(2 Suppl):S46–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Blohme I, Larko O. Premalignant and malignant skin lesions in renal transplant patients. Transplantation. 1984; 37:165–167.PubMedCrossRefGoogle Scholar
  17. 17.
    Oh JE, Ahn C, Yang JS, Min KW, Song KY, Kim SJ, Han JS, Kim S, Lee JS. Malignant proliferating trichilemmal tumour in renal transplantation. Nephrol Dial Transplant. 1997; 12(12):2768–71.PubMedCrossRefGoogle Scholar
  18. 18.
    Happenreijs VPT, Reuser TTQ, Maay CM, De Keizer RJW, Maurits MP. Syringomatous carcinoma of the eyelid and orbit: a clinical and histopathological challenge. Br J Ophthamol. 1997; 81:668–72.CrossRefGoogle Scholar
  19. 19.
    Chastain MA, Millikan LE. Pilomatrix dysplasia in an immunosuppressed patient. J Am Acad Dermatol. 2000; 43:118–22.PubMedCrossRefGoogle Scholar
  20. 20.
    Ramsay HM, Fryer AA, Reece S, Smith AG, Harden PN. Clinical risk factors associated with nonmelanoma skin cancer in renal transplant recipients. Am J Kidney Dis. 2000; 36(1):167–76.PubMedCrossRefGoogle Scholar
  21. 21.
    Euvrard S, Kanitakis J, Cochat P, Cambazard F, Claudy A. Skin diseases in children with organ transplants. J Am Acad Dermatol. 2001; 44(6):932–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Snow S, Madjar DD, Hardy S, Bentz M, Lucarelli MJ, Bechard R, Aughenbaugh W, McFadden T, Sharata H, Dudley C, Landeck A. Microcystic adnexal carcinoma: report of 13 cases and review of the literature. Dermatol Surg. 2001; 27(4):401–8.PubMedCrossRefGoogle Scholar
  23. 23.
    Plunkett TA, Hanby AM, Miles DW, Rubens RD. Metastatic eccrine porocarcinoma: Response to docetaxel (Taxotere). Ann Oncol. 2001; 12:411–414.PubMedCrossRefGoogle Scholar
  24. 24.
    Garrett AB, Scott KA. Trichilemmal carcinoma: a case report of a rare skin cancer occurring in a renal transplant patient. Transplantation. 2003; 76(7):1131.PubMedCrossRefGoogle Scholar
  25. 25.
    Bordea C, Wojnarowska F, Millard PR, Doll H, Welsh K, Morris PJ. Skin cancers in renal-transplant recipients occur more frequently than previously recognized in a temperate climate. Transplantation. 2004; 77(4):574–9. Review.PubMedCrossRefGoogle Scholar
  26. 26.
    Mudhar HS, Parsons MA, Farr R, Ford A, Gudgeon P, Collins C, Chang BY. Steatosebocystadenoma: a novel cystic sebaceous neoplasm in an immunosuppressed individual. Histopathology. 2005; 47(4):429–3.PubMedCrossRefGoogle Scholar
  27. 27.
    Harwood CA, McGregor JM, Swale VJ, Proby CM, Leigh IM, Newton R, Khorshid SM, Cerio R. High frequency and diversity of cutaneous appendageal tumors in organ transplant recipients. J Am Acad Dermatol. 2003; 48(3):401–8.PubMedCrossRefGoogle Scholar
  28. 28.
    Heaphy MR, Shamma HN, Hickmann M, White MJ. Cyclosporine-induced folliculodystrophy. J Am Acad Dermatol. 2004; 50:318–22.CrossRefGoogle Scholar
  29. 29.
    Harwood CA, Swale VJ, Bataille VA, Quinn AG, Ghali L, Patel SV et al. An association between sebaceous carcinoma and microsatellite instability in immunosuppressed organ transplant recipients. J Invest Dermatol; 2001; 116:246–53.PubMedCrossRefGoogle Scholar
  30. 30.
    O’Donovan P, Perrett CM, Zhang X, Montaner B, Xu YZ, Harwood CA, McGregor JM, Walker SL, Hanaoka F, Karran P. Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science. 2005; 309(5742):1871–4.PubMedCrossRefGoogle Scholar
  31. 31.
    Brash DE, Rudolph JA, Simon JA, Lin A, McKenna GJ, Baden HP, Halperin AJ, Ponten J. A role for sunlight in skin cancer: UV induced p53 mutations in squamous-cell carcinoma. Proc Natl Acad Sci USA.1991;88:10124–8.PubMedCrossRefGoogle Scholar
  32. 32.
    De Gruijl FR. Skin cancer and solar UV radiation. Eur J Cancer. 1999; 35:2003–9.PubMedCrossRefGoogle Scholar
  33. 33.
    Boukamp P. Non-melanoma skin cancer: what drives tumor development and progression? Carcinogenesis. 2005; 26:1657–87.PubMedCrossRefGoogle Scholar
  34. 34.
    Ullrich SE. Mechanisms underlying UV-induced immune suppression. Mutation Res. 2005; 571:185–205.PubMedGoogle Scholar
  35. 35.
    Kruse R, Rutten A, Lamberti C, Hosseiny-Malayeri HR, Wang Y, Ruelfs C, Jungck M, Mathiak M, Ruzicka T, Hartschuh W, Bisceglia M, Friedl W, Propping P. Muir-Torre phenotype has a frequency of DNA mismatch-repair-gene mutations similar to that in hereditary nonpolyposis colorectal cancer families defined by the Amsterdam criteria. Am J Hum Genet. 1998; 63:63–70.PubMedCrossRefGoogle Scholar
  36. 36.
    Bignell GR, Warren W, Seal S, Takahashi M, Rapley E, Barfoot R, Green H, Brown C, Biggs PJ, Lakhani SR, Jones C, Hansen J, Blair E, Hofmann B, Siebert R, Turner G, Evans DG, Schrander-Stumpel C, Beemer FA, van Den Ouweland A, Halley D, Delpech B, Cleveland MG, Leigh I, Leisti J, Rasmussen S. Identification of the familial cylindromatosis tumour-suppressor gene. Nat Genet. 2000; 25(2):160–5.PubMedCrossRefGoogle Scholar
  37. 37.
    Leonard N, Chaggar R, Jones C, Takahashi M, Nikitopoulou A, Lakhani SR. Loss of heterozygosity at cylindromatosis gene locus CYLD, in sporadic skin adnexal tumours. J Clin Pathol. 2001; 54:689–92.PubMedGoogle Scholar
  38. 38.
    Harada H, Hashimoto KY, Ko MSH. The gene for multiple trichoepitheliomas maps to chromosome 9p21. J Invest Dermatol. 1996; 107:41–43.PubMedCrossRefGoogle Scholar
  39. 39.
    Matt D, Xin H, Vortmeyer AO, Zhuang Z, Burg G, Boni R. Sporadic trichoepithelioma demonstrates deletions at 9q22.3. Arch Dermatol. 2000; 136:657–60.PubMedCrossRefGoogle Scholar
  40. 40.
    Liaw D, Marsh DJ, Li J, Dahia PL, Wang SI, Zheng Z, Bose S, Call KM, Tsou HC, Peacocke M, Eng C, Parsons R. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet. 1997; 16(1):64–7.PubMedCrossRefGoogle Scholar
  41. 41.
    Sundberg JP, O’Banion MK, Shima A, Knupp C, Reichmann ME. Papillomas and carcinomas associated with a papillomavirus in European Harvest mice (Micromys minutus). Vet Pathol. 1988; 25:356–61.PubMedCrossRefGoogle Scholar
  42. 42.
    Herber R, Liem A, Pitot H et al. Squamous epithelial hyperplasia and carcinoma in mice transgenic for the human papillomavirus type 16E7 oncogene. J Virol. 1996; 70:1873–81.PubMedGoogle Scholar
  43. 43.
    Hayashi N, Furihata M, Ohtsuki Y, Ueno H. Search for accumulation of p53 protein and detection of human papillomavirus genomes in sebaceous gland carcinoma of the eyelid. Virchows Archiv. 1994; 424:503–9.PubMedCrossRefGoogle Scholar
  44. 44.
    Rohwedder A, Keminer O, Hendricks C, Scaller J. Detection of HPV DNA in trichilemmomas by polymerase chain reaction. J Med Virol. 1997; 51:119–25.PubMedCrossRefGoogle Scholar
  45. 45.
    Leonardi CL, Zhu WY, Kinsey WH, Penneys NS. Trichilemmomas are not associated with human papillomavirus DNA. J Cutan Pathol. 1991; 18(3):193–7.PubMedCrossRefGoogle Scholar
  46. 46.
    Assadoullina A, Bialasiewicz AA, de Villiers EM, Richard G. Detection of HPV-20, HPV-23, and HPV-DL332 in a solitary eyelid syringoma. Am J Ophthalmol. 2000; 129:99–101.PubMedCrossRefGoogle Scholar
  47. 47.
    Carlson JW, McGennen RC, Gomez R, Longbella C, Carter J, Carson LF. Sebaceous carcinoma of the vulva: a report and review of the literature. Gynecol Oncol. 1996; 60:489–91.PubMedCrossRefGoogle Scholar
  48. 48.
    Escalonilla P, Grilli R, Canamero M, Soriano ML, Frina MC, Manzarbeitia F, Sainz R, Matsukura T, Requena L. Sebaceous carcinoma of the vulva. Am J Dermatopathol. 1999; 21:468–72.PubMedCrossRefGoogle Scholar
  49. 49.
    Egawa K. Eccrine-centred distribution of human papillomavirus 63 infection in the epidermis of the plantar skin. Br J Dermatol. 2005; 152(5):993–6.PubMedCrossRefGoogle Scholar
  50. 50.
    Hsu PJ, Liu CH, Huang CJ. Mixed tubulopapillary hidradenoma and syringocystadenoma papilliferum occurring as a verrucous tumor. J Cutan Pathol. 2003; 30(3):206–10.PubMedCrossRefGoogle Scholar
  51. 51.
    Requena L, Kutzner H, Hurt MA, Danta Cruz DJ, Mehregan DA, Mehregan DR, Mengesha YM, Kohler S, Argenyi ZB, McNiff J, Rudolph P, Sangueza OP. Malignant tumours with apocrine and eccrine differentiation. In: World Health Organisation Classification of Tumours: Skin Tumours (Edited by LeBoit PE, Burg G, Weedon D, Sarasin Al); IARC Press, Lyon, 2006. pp. 125–151.Google Scholar
  52. 52.
    Huet P, Dandurand M, Pignodel C, Guillot B. Metastasizing eccrine porocarcinoma: report of a case and review of the literature. J Am Acad Dermatol. 1996; 35(5 Pt 2):860–4.PubMedCrossRefGoogle Scholar
  53. 53.
    McNiff J, McCalmont TH, Requena L, Sangueza OP, Vassalo C, Rosso R, Borroni G, Glusac EJ, Pichardo RO. Benign tumours with apocrine and eccrine differentiation. pp 139–148. In: World Health Organisation Classification of Tumours: Skin Tumours (Edited by LeBoit PE, Burg G, Weedon D, Sarasin A; IARC Press, Lyon, 2006).Google Scholar
  54. 54.
    de Berker DA, Taylor AE, Quinn AG, Simpson NB. Sebaceous hyperplasia in organ transplant recipients: shared aspects of hyperplastic and dysplastic processes? J Am Acad Dermatol. 1996; 35(5 Pt 1):696–9.PubMedGoogle Scholar
  55. 55.
    Mak R, Perrett C, Proby CM, Harwood CA. Sebaceous gland hyperplasia is common and therapeutically challenging in organ transplant recipients. Br J Dermatol. 2006; 155 (Suppl 1):36.Google Scholar
  56. 56.
    Moloney FJ, Keane S, O’Kelly P, Conlon PJ, Murphy GM. The impact of skin disease following renal transplantation on quality of life. Br J Dermatol. 2005 Sep;153(3):574–8.Google Scholar
  57. 57.
    Salard D, Parriaux N, Derancourt C, Aubin F, Bresson-Hadni S, Miguet JP, Laurent R. Cutaneous complications following liver transplantation: epidemiologic and clinical study in 86 patients. Ann Dermatol Venereol. 2002; 129(10 Pt 1):1134–8.PubMedGoogle Scholar
  58. 58.
    Salim A, Reece SM, Smith AG, Harrison D, Ramsay HM, Harden PN, Fryer AA. Sebaceous hyperplasia and skin cancer in patients undergoing renal transplant. Am Acad Dermatol. 2006; 55(5):878–81.CrossRefGoogle Scholar
  59. 59.
    Perrett CM, McGregor J, Barlow RJ, Karran P, Proby C, Harwood CA. Topical photodynamic therapy with methyl aminolevulinate to treat sebaceous hyperplasia in an organ transplant recipient. Arch Dermatol. 2006; 142(6):781–2.PubMedCrossRefGoogle Scholar
  60. 60.
    Walther T, Hohenleutner U, Landthaler M. Sebaceous gland hyperplasia as a side effect of cyclosporin A. Treatment with the CO2 laser. Dtsch Med Wochenschr. 1998; 123(25–26):798–800.PubMedCrossRefGoogle Scholar
  61. 61.
    Pang SM, Chau YP. Cyclosporin-induced sebaceous hyperplasia in renal transplant patients. Ann Acad Med Singapore. 2005; 34(5):391–3.PubMedGoogle Scholar
  62. 62.
    Harwood CA, Proby CM, McGregor JM, Sheaff MT, Leigh IM, Cerio R. Clinicopathologic features of skin cancer in organ transplant recipients: a retrospective case-control series. J Am Acad Dermatol. 2006; 54(2):290–300.PubMedCrossRefGoogle Scholar
  63. 63.
    Torre D. Multiple sebaceous tumours. Arch Dermatol. 1968; 98:549–51.PubMedCrossRefGoogle Scholar
  64. 64.
    Jiricny J. Replication errors: cha(lle)nging the genome. EMBO J. 1998; 22:6427–36.CrossRefGoogle Scholar
  65. 65.
    Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, Meltzer SJ, Rodriguez-Bigas MA, Fodde R, Ranzani GN, Srivastava S. A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998; 58:5248–5257.PubMedGoogle Scholar
  66. 66.
    Swann PF, Waters TR, Moulton DC, Xu Y-Z, Zheng Q, Edwards M, Mace R. Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine. Science. 1996; 273:1109–11.PubMedCrossRefGoogle Scholar
  67. 67.
    Karran P, Bignami M. DNA damage tolerance, mismatch repair and genome instability. BioEssays. 1994; 16:833–9.PubMedCrossRefGoogle Scholar
  68. 68.
    Glaab WE, Risinger JI, Umar A, Barrett JC, Kunkel TA, Tindall KR. Resistance to 6-thioguanine in mismatch repair-deficient human cancer cell lines correlates with an increase in induced mutations at the HPRT locus. Carcinogenesis. 1998; 19(11):1931–7.PubMedCrossRefGoogle Scholar
  69. 69.
    Zouboulis CC, Boschnaknow A. Chronological ageing and photoageing in the human sebaceous gland. Clin Exp Dermatol. 2001; 26:600–7.PubMedCrossRefGoogle Scholar
  70. 70.
    Perrett CM, Walker SL, O’Donovan P, Warwick J, Harwood CA, Karran P, McGregor JM Azathioprine treatment photosensitizes human skin to ultraviolet A radiation. Br J Dermatol. 2008; 159(1):198–204.PubMedCrossRefGoogle Scholar
  71. 71.
    Lindelof B, Sigurgeirsson B, Gabel H, Stern RS. Incidence of skin cancer in 5356 patients following organ transplantation. Br J Dermatol. 2000; 143:614–18.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Catherine A. Harwood
    • 1
    • 2
  • Charlotte M. Proby
    • 3
  • Rino Cerio
    • 4
  1. 1.Center for Cutaneous Research, Institute of Cell and Molecular ScienceBarts and The London School of Medicine and Dentistry, Queen Mary University of LondonLondon
  2. 2.Department of DermatologyBarts and the London NHS TrustLondonUnited Kingdom
  3. 3.Division of Surgery and OncologyCollege of Medicine, Dentistry and Nursing, University of Dundee, Ninewells HospitalDundeeUnited Kingdom
  4. 4.Departments of Dermatology and Pathology, Barts and The London NHS TrustInstitute of Cell and Molecular Science, Barts and The London School of Medicine and DentistryLondonUnited Kingdom

Personalised recommendations